Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Ipsen    IPN   FR0010259150

IPSEN

(IPN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Ipsen : After the accumulation, an upward acceleration ?

share with twitter share with LinkedIn share with facebook
09/15/2020 | 02:57am EDT
long trade
Live
Entry price : 91€ | Target : 105€ | Stop-loss : 84€ | Potential : 15.38%
After accumulation, acceleration. Timing appears favorable to go long in shares of Ipsen and to anticipate an exit of the trading range on the upside.
Investors have an opportunity to buy the stock and target the € 105.
Ipsen : Ipsen : After the accumulation, an upward acceleration ?
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • Ipsen accounts for 5.40 % of our European Portfolio. A trade is currently open since 10/10/2019 with a purchase price of € 69.46. Discover the other 19 stocks of the European portfolio managed by the MarketScreener portfolio management team.

Strengths
  • The group's high margin levels account for strong profits.

Weaknesses
  • The share is close to its long-term resistance in weekly data. Therefore, the potential should be limited. However, a further bullish movement when crossing this resistance will be a positive signal.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart
Subsector Pharmaceuticals - NEC
1st jan.Capitalization (M$)Investor Rating
IPSEN17.53%9 120
JOHNSON & JOHNSON2.27%392 765
ROCHE HOLDING AG9.27%322 209
MERCK & CO., INC.-5.65%217 034
PFIZER, INC.-6.02%203 549
NOVARTIS AG-9.76%200 978
NOVO NORDISK A/S12.50%161 415
ABBVIE INC.1.77%159 029
ASTRAZENECA PLC14.97%148 689
AMGEN INC.2.76%145 088
ELI LILLY AND COMPANY17.30%139 751
More Results

share with twitter share with LinkedIn share with facebook

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials
Sales 2020 2 706 M 3 206 M 3 206 M
Net income 2020 501 M 594 M 594 M
Net Debt 2020 717 M 849 M 849 M
P/E ratio 2020 15,4x
Yield 2020 1,12%
Capitalization 7 688 M 9 120 M 9 108 M
EV / Sales 2020 3,11x
EV / Sales 2021 2,82x
Nbr of Employees 5 807
Free-Float 42,2%
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 91,56 €
Last Close Price 92,85 €
Spread / Highest target 8,78%
Spread / Average Target -1,39%
Spread / Lowest Target -14,7%
EPS Revisions
Managers
NameTitle
David G. Loew Chief Executive Officer & Director
Marc M. P. de Garidel Non-Executive Chairman
Aymeric Le Chatelier Chief Financial Officer & Executive Vice President
Aidan Murphy Executive Vice President-Technical Operations
Howard Mayer Executive Vice President-Research & Development